Trial · NCT01043640
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients With Donor Derived Engraftment | Day 100 Post Transplant | Donor derived engraftment is defined as 80 percent or greater donor cells in the recipient's bone marrow and blood cells. |
| Secondary | Number of Patients With Grade 0 Graft-Versus-Host Disease (GVHD) | Day 100 Post Transplant | GVHD grading is performed using modified Glucksberg criteria and is as follows: grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4 |
| Secondary | Number of Patients With Grade 1 Graft-Versus-Host Disease (GVHD) | Day 100 Post Transplant | GVHD grading is performed using modified Glucksberg criteria and is as follows: grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4 |
| Secondary | Number of Patients With Grade 2 Graft-Versus-Host Disease (GVHD) | Day 100 Post Transplant | GVHD grading is performed using modified Glucksberg criteria and is as follows: grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4 |
| Secondary | Number of Patients With Grade 3 Graft-Versus-Host Disease (GVHD) | Day 100 Post Transplant | GVHD grading is performed using modified Glucksberg criteria and is as follows: grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4 |
| Secondary | Number of Patients With Grade 4 Graft-Versus-Host Disease (GVHD) | Day 100 Post Transplant | GVHD grading is performed using modified Glucksberg criteria and is as follows: grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4 |
| Secondary | Number of Patients Who Died Peri-Transplant | By Day 100 Post Transplant | Peri-transplant is defined as within 100 days of transplant. |
| Secondary | Donor Cell Chimerism Following Transplant | Day 28 | Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. |
| Secondary | Donor Cell Chimerism Following Transplant | Day 42 | Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. |
| Secondary | Donor Cell Chimerism Following Transplant | Day 100 | Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. |
| Secondary | Donor Cell Chimerism Following Transplant | 6 months | Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. |
| Secondary | Donor Cell Chimerism Following Transplant | One year | Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01043640/registered